Adipotide: Scientific Profile

Publicado el 12 de julio de 2026 · Actualizado el 17 de julio de 2026

Adipotide (CAS 859216-15-2) is a proapoptotic chimeric peptide targeting the vasculature of white adipose tissue, explored in metabolic research. It combines a recognition domain (CKGGRAKDC) that binds prohibitin in the endothelium of fat tissue with a mitochondrial-disruptor segment D(KLAKLAK)2. Compound for research use only.

Adipotide (Spanish name Adipotida), also designated prohibitin-targeting peptide 1, is a low-molecular-weight synthetic chimeric peptide (formula C111H206N36O28S2; approximate molecular weight of 2557.21 g/mol; CAS 859216-15-2) designed as an antiangiogenic agent directed specifically against the vasculature that supplies white adipose tissue. Structurally it belongs to the class of vascular homing peptides and has been studied mainly in the context of research on obesity, energy metabolism, and adipose tissue remodeling. It is a compound intended exclusively for laboratory research use.

From a structural point of view, Adipotide is a bifunctional molecule described by the sequence CKGGRAKDC-GG-D(KLAKLAK)2. The first module, the cyclic nonapeptide CKGGRAKDC, acts as a recognition or "homing" domain: it binds with relative selectivity to prohibitin, a protein that in animal models has been reported to be enriched on the surface of the endothelial cells of the microvessels that nourish white fat. The second module, D(KLAKLAK)2, is a proapoptotic peptide composed of D-amino acids that, once internalized, disrupts the mitochondrial membrane and triggers programmed cell death. The two domains are connected by a short glycine linker (GG). The use of D-amino acids in the effector segment confers resistance to degradation by proteases, which was a relevant design element in its original characterization. This concept of a "targeting peptide coupled to a proapoptotic module" was developed from the work on affinity-based vascular mapping (phage display) associated with the researchers Wadih Arap and Renata Pasqualini.

The proposed mechanism of action in preclinical models is articulated in two steps. First, the CKGGRAKDC domain directs the molecule toward the endothelium of the blood vessels of white adipose tissue through its affinity for prohibitin exposed on the luminal surface. Second, after binding and internalization, the D(KLAKLAK)2 segment targets the mitochondria and causes the disruption of their membrane, activating the apoptosis of the target endothelial cells. The mechanistic hypothesis is that the selective elimination of the vascular bed that supplies the fat deprives the adipocytes of blood supply, inducing their metabolic regression. In animal models this has been associated with reduction of fat mass, decrease in body weight, and changes in metabolic parameters such as insulin sensitivity. It is important to emphasize that this mechanism is based on the premise of selective vascular targeting and that the extrapolation to other vascular beds or species is not fully resolved.

As for documented research applications, Adipotide has been explored in rodent models of obesity (diet-induced and genetic) and, notably, in a study with obese non-human primates, where weight loss and reduction of adiposity were observed during the administration period. These findings positioned the compound as a tool of interest for studying the relationship between adipose tissue angiogenesis and energy homeostasis, as well as for investigating the reversibility of fat-tissue expansion. It has also been used as a conceptual probe to validate prohibitin as a tissue-specific vascular marker. Beyond the metabolic domain, the same proapoptotic targeting backbone has inspired exploratory research in vascular oncology, given that analogous "homing" strategies have been studied in other contexts of tumor endothelial biology.

The level of evidence must be interpreted honestly: Adipotide is at a fundamentally preclinical stage. The bulk of the knowledge comes from animal studies (rodents and non-human primates) and from in vitro work on endothelial targeting and apoptosis. There is no robust base of conclusive clinical trials supporting an established efficacy and safety profile in humans; the early clinical developments that were proposed did not lead to a therapeutic approval. A critical point repeatedly noted in the preclinical literature is renal toxicity: in animal models, structural and functional changes in the kidney associated with administration of the peptide have been reported, which constitutes a central limitation for any interpretation of its results. For this reason, any favorable metabolic data must be read within the framework of a narrow safety margin and a toxicological profile that is not yet fully characterized.

In summary, Adipotide is a chimeric vascular-targeting peptide with a dual mechanism—recognition of prohibitin on the endothelium of white adipose tissue and proapoptotic mitochondrial disruption—that has served as a valuable tool in research into the vascular biology of fat and its role in energy metabolism. Its scientific interest lies in validating the concept of selective ablation of the adipose vascular bed, but its development remains limited by the absence of solid clinical evidence and by signs of toxicity, particularly at the renal level, documented in animal models. These considerations keep it firmly in the realm of the research reagent and not that of an established therapeutic application.